Patrick Vermersch (University of Lille and CHU Lille, Lille, France) shares promising findings and expert insight from the phase 3 study of masitinib for the treatment of progressive multiple sclerosis (ClinicalTrials.gov identifier: NCT01433497). This discussion was based on his MSVirtual2020 presentation: FC04.01 Masitinib in primary progressive (PPMS) and non-active secondary progressive (nSPMS) multiple sclerosis: Results from phase 3 study AB07002.
1. Tell us about the aims, design and major key findings of the AB07002 study. (0:06)
2. What is the clinical significance of these findings and what future studies are planned? (5:01)
See also the 1st part of this interview here.
Disclosures: Dr Vermersch reports receiving honoraria and consulting fees from Biogen, Celgene, Novartis, Sanofi-Genzyme, Merck, Roche and Teva; he also receives research support from Novartis, Roche and Sanofi-Genzyme.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020.
Share this Video
Related Videos In Multiple Sclerosis
Simon Faissner, EAN 2023: Safety and efficacy of diroximel fumarate in older patients with multiple sclerosis from the phase III EVOLVE-MS-1 study
Oral diroximel fumarate (DRF) has similar efficacy/safety to dimethyl fumarate in relapsing-remitting multiple sclerosis (RRMS), but improved GI tolerability. In the from EVOLVE-MS-1 study, safety/efficacy of DRF was assessed in patients with RRMS aged >=55 years. Dr Simon Faissner (Ruhr-University Bochum, Germany) summarizes the take-home messages from his presentation of the results of the study. The abstract ‘EPO-160 […]
Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis
The phase III clinical studies Ultimate I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the aim, designs and outcomes of these studies as well as the subpopulation analyses […]
Enrique Alvarez, AAN 2023: Ublituximab for participants with relapsing multiple sclerosis
The phase III clinical studies ULTIMATE I (NCT03277261) and II (NCT03277248) evaluate the efficacy and safety of ublituximab in patients with relapsing multiple sclerosis compared with teriflunomide. In this touchNEUROLOGY interview, Dr Enrique Alvarez (University of Colorado, Boulder, CO, USA) discusses the unmet needs of this population and the mechanism of action of ublituximab. The […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!